表紙
市場調查報告書

動脈粥狀硬化性心血管疾病:開發中產品分析

Atherosclerosis - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 232865
出版日期 內容資訊 英文 252 Pages
訂單完成後即時交付
價格
Back to Top
動脈粥狀硬化性心血管疾病:開發中產品分析 Atherosclerosis - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 252 Pages
簡介

動脈粥狀硬化性心血管疾病,是由於高密度脂蛋白積蓄造成動脈肥厚化並硬化的疾病。會阻礙血流、引起嚴重的心血管障礙。症狀有胸部疼痛、四肢或動脈阻塞的部位疼痛、呼吸急促、疲勞感、意識障礙、血流不足造成腿部肌肉無力等。

本報告提供動脈粥狀硬化性心血管疾病的治療藥開發情形調查分析,提供開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

動脈粥狀硬化性心血管疾病概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11523IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Pipeline Review, H2 2019, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.

Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 2, 2, 3, 6, 1, 36, 13 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 18 and 2 molecules, respectively.

Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Atherosclerosis - Overview
  • Atherosclerosis - Therapeutics Development
  • Atherosclerosis - Therapeutics Assessment
  • Atherosclerosis - Companies Involved in Therapeutics Development
  • Atherosclerosis - Drug Profiles
  • Atherosclerosis - Dormant Projects
  • Atherosclerosis - Discontinued Products
  • Atherosclerosis - Product Development Milestones
  • Appendix

List of Tables

  • Table 1: Number of Products under Development for Atherosclerosis, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 5: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 6: Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Table 7: Products under Development by Companies, H2 2019
  • Table 8: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 9: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Table 10: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Table 11: Products under Development by Universities/Institutes, H2 2019
  • Table 12: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
  • Table 13: Number of Products by Stage and Target, H2 2019
  • Table 14: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Table 15: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Table 16: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 17: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Table 18: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Table 19: Number of Products by Stage and Route of Administration, H2 2019
  • Table 20: Number of Products by Stage and Molecule Type, H2 2019
  • Table 21: Atherosclerosis - Pipeline by 13therapeutics Inc, H2 2019
  • Table 22: Atherosclerosis - Pipeline by Abcentra LLC, H2 2019
  • Table 23: Atherosclerosis - Pipeline by ABIONYX Pharma SA, H2 2019
  • Table 24: Atherosclerosis - Pipeline by AFFiRiS AG, H2 2019
  • Table 25: Atherosclerosis - Pipeline by Allysta Pharmaceuticals Inc, H2 2019
  • Table 26: Atherosclerosis - Pipeline by Amgen Inc, H2 2019
  • Table 27: Atherosclerosis - Pipeline by Annexin Pharmaceuticals AB, H2 2019
  • Table 28: Atherosclerosis - Pipeline by AptaBio Therapeutics Inc, H2 2019
  • Table 29: Atherosclerosis - Pipeline by Artery Therapeutics Inc, H2 2019
  • Table 30: Atherosclerosis - Pipeline by Asdera, H2 2019
  • Table 31: Atherosclerosis - Pipeline by AstraZeneca Plc, H2 2019
  • Table 32: Atherosclerosis - Pipeline by Athera Biotechnologies AB, H2 2019
  • Table 33: Atherosclerosis - Pipeline by Auxagen Inc, H2 2019
  • Table 34: Atherosclerosis - Pipeline by Band Therapeutics LLC, H2 2019
  • Table 35: Atherosclerosis - Pipeline by BBN Cardio Therapeutics, H2 2019
  • Table 36: Atherosclerosis - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • Table 37: Atherosclerosis - Pipeline by Centeer BioTherapeutics Ltd Co, H2 2019
  • Table 38: Atherosclerosis - Pipeline by CohBar Inc, H2 2019
  • Table 39: Atherosclerosis - Pipeline by Corbus Pharmaceuticals Inc, H2 2019
  • Table 40: Atherosclerosis - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
  • Table 41: Atherosclerosis - Pipeline by DoNatur GmbH, H2 2019
  • Table 42: Atherosclerosis - Pipeline by Esperion Therapeutics Inc, H2 2019
  • Table 43: Atherosclerosis - Pipeline by General Regeneratives Shanghai Ltd, H2 2019
  • Table 44: Atherosclerosis - Pipeline by GenKyoTex SA, H2 2019
  • Table 45: Atherosclerosis - Pipeline by Immusoft Corp, H2 2019
  • Table 46: Atherosclerosis - Pipeline by Innolife Co Ltd, H2 2019
  • Table 47: Atherosclerosis - Pipeline by Inotrem SA, H2 2019
  • Table 48: Atherosclerosis - Pipeline by Inspyr Therapeutics Inc, H2 2019
  • Table 49: Atherosclerosis - Pipeline by Iproteos SL, H2 2019
  • Table 50: Atherosclerosis - Pipeline by Jenrin Discovery Inc, H2 2019
  • Table 51: Atherosclerosis - Pipeline by Kaleido Biosciences Inc, H2 2019
  • Table 52: Atherosclerosis - Pipeline by KineMed Inc, H2 2019
  • Table 53: Atherosclerosis - Pipeline by Kiromic Inc, H2 2019
  • Table 54: Atherosclerosis - Pipeline by Kowa Co Ltd, H2 2019
  • Table 55: Atherosclerosis - Pipeline by LG Chem Ltd, H2 2019
  • Table 56: Atherosclerosis - Pipeline by LipimetiX Development Inc, H2 2019
  • Table 57: Atherosclerosis - Pipeline by Mperia Therapeutics Inc, H2 2019
  • Table 58: Atherosclerosis - Pipeline by Novartis AG, H2 2019
  • Table 59: Atherosclerosis - Pipeline by NuSirt Biopharma Inc, H2 2019
  • Table 60: Atherosclerosis - Pipeline by Omeros Corp, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Atherosclerosis, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Top 10 Targets, H2 2019
  • Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
  • Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
  • Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top